Zoetis (NYSE:ZTS) Stock Bumped Up to “Hold” by Zacks Research

Zacks Research upgraded shares of Zoetis (NYSE:ZTS) from a strong sell rating to a hold rating in a research note released on Monday,Zacks reports.

Other analysts have also issued research reports about the stock. TD Cowen cut their price objective on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 25th. Stifel Nicolaus decreased their target price on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research report on Thursday, August 20th. William Blair restated a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Barclays lowered their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Finally, UBS Group upped their target price on Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Tuesday. Seven research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $98.40.

Zoetis Price Performance

Shares of ZTS stock opened at $78.25 on Monday. The stock’s 50-day simple moving average is $74.84 and its 200-day simple moving average is $94.35. Zoetis has a fifty-two week low of $68.77 and a fifty-two week high of $147.46.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period last year, the firm earned $1.76 EPS. The company’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts predict that Zoetis will post 6.15 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Physician Wealth Advisors Inc. grew its position in shares of Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after acquiring an additional 91 shares during the period. Lipe & Dalton boosted its position in Zoetis by 2.2% during the first quarter. Lipe & Dalton now owns 4,698 shares of the company’s stock worth $555,000 after purchasing an additional 102 shares in the last quarter. Root Financial Partners LLC boosted its position in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. Rexford Capital Inc. grew its holdings in Zoetis by 5.3% in the first quarter. Rexford Capital Inc. now owns 2,352 shares of the company’s stock valued at $278,000 after purchasing an additional 118 shares during the period. Finally, Valmark Advisers Inc. grew its holdings in Zoetis by 7.7% in the first quarter. Valmark Advisers Inc. now owns 1,747 shares of the company’s stock valued at $207,000 after purchasing an additional 125 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.